Bela Kis

Dr. Bela Kis


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AGAlexandra Gangi
Alexandra Gangi
JSJehan Shah
Jehan Shah
NHNathan Hatfield
Nathan Hatfield
JSJohnna Smith
Johnna Smith
JSJennifer Sweeney
Jennifer Sweeney
BKBela Kis
Bela Kis

1 December 2017 in Clinical Radiology
Verified
Journal Article
Closed access
MMM. Mills
M. Mills
JCJ. Choi
J. Choi
GEG. El-Haddad
G. El-Haddad
JSJ. Sweeney
J. Sweeney
BBB. Biebel
B. Biebel
BKBela Kis
Bela Kis

9 September 2016 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
BKBela Kis
Bela Kis
MMMatthew Mills
Matthew Mills
SHSarah E. Hoffe
Sarah E. Hoffe
Diagnostic and Interventional Radiology

1 September 2017 in Cancer Control
Verified
Journal Article
Open access
BKBela Kis
Bela Kis
GEGhassan El-Haddad
Ghassan El-Haddad
RSRahul A. Sheth
Rahul A. Sheth
NPNainesh S. Parikh
Nainesh S. Parikh
SGSuvranu Ganguli
Suvranu Ganguli
KBKaren T. Brown
Karen T. Brown
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver-directed therapies provide survival benefit for patients with HCC and IHC compared to best medical treatment and have lower comorbid risks compared to surgical resection. These treatment options should be considered, especially in patients with unresectable disease.

1 March 2021 in Clinical Imaging
Verified
Journal Article
Closed access
ZMZachary Makovich
Zachary Makovich
JLJerryRay Logemann
JerryRay Logemann
LCLiwei Chen
Liwei Chen
RMRahul Mhaskar
Rahul Mhaskar
JCJunsung Choi
Junsung Choi
BKBela Kis
Bela Kis

31 October 2019 in Seminars in Interventional Radiology
Verified
Journal Article
Closed access
PDF file
JSJennifer Sweeney
Jennifer Sweeney
NPNainesh Parikh
Nainesh Parikh
GEGhassan El-Haddad
Ghassan El-Haddad
BKBela Kis
Bela Kis
Intrahepatic cholangiocarcinoma is the second most common primary liver cancer but represents only a small portion of all primary liver cancers. At the time of diagnosis, patients are often not surgical candidates due to tumor burden of other comorbidities. In addition, there is a very high rate of tumor recurrence after resection. Local regional therapies, specifically ablative therapies of radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation, have proven to be beneficial with other hepatic tumors. The purpose of this review is to provide an overview and update of the medical literature demonstrating ablative therapy as a treatment option for intrahepatic cholangiocarcinoma.